Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in Pe
The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia. The main questions it aims to answer are: Can using reticulocyte hemoglobin equivalent (RET-He) to guide intravenous (IV) iron treatmen
| Condition(s) | Hemodialysis, Anemia in End Stage Renal Disease |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia. The main questions it aims to answer are: Can using reticulocyte hemoglobin equivalent (RET-He) to guide intravenous (IV) iron treatment be as effective as using transferrin saturation (TSAT)? Does the method used to guide iron treatment affect outcomes such as death, heart problems, hospitalizations, infections, or the need for blood transfusions? Researchers will compare RET-He-guided iron treatment with TSAT-guided iron treatment to see if RET-He works just as well and has similar or better outcomes. Participants will: Receive IV iron based on either RET-He or TSAT levels Have blood tests done at the star |
| Who can participate | Inclusion Criteria: * Adult (age 18-80 years) * ESKD on chronic hemodialysis ≥ 6 months * EPO therapy ≥ 6 months * Hb \< 13.0 g/dL in male, \< 12.0 g/dL in female Exclusion Criteria: * Serum ferritin \> 800 ng/mL or TSAT \> 40% * Active infection or malignancy * Hematologic disease including thalassemia major, hemolysis, myelofibrosis or myelodysplastic disease * History of marrow suppressive or immunosuppressive medications in past 6 months * History of active heart failure and recent myocardial infarction /stroke in past 6 months * History of GI or external bleeding or receiving blood transfusion in past 6 months |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | King Chulalongkorn Memorial Hospital |
| Locations | Pathumwan, Bangkok, Thailand |
| Start date | 2025-01-31 |
| NCT ID | NCT06906835 |
| Official listing | https://clinicaltrials.gov/study/NCT06906835 |